| Family: | First Trust |
| Name: | First Trust NYSE Arca Biotechnology Index Fund |
| Inception Date: | 19-Jun-2006 |
| Termination Date: | |
| Investment Objective: | The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible before fees and expenses the price and yield of the NYSE Arca Biotechnology Index. |
| Prospectus | |
| Top 10 Holdings | ||
| Halozyme Therapeutics Inc. | HALO | 4.4067% |
| Corcept Therapeutics Inc. | CORT | 3.9375% |
| NeoGenomics Inc. | NEO | 3.9135% |
| Natera Inc. | NTRA | 3.8260% |
| Regeneron Pharmaceuticals Inc. | REGN | 3.8003% |
| BeOne Medicines Ltd. (ADR) | ONC | 3.6744% |
| Sarepta Therapeutics Inc. | SRPT | 3.6334% |
| Repligen Corporation | RGEN | 3.5780% |
| argenx SE (ADR) | ARGX | 3.5712% |
| Genmab A/S (ADR) | GMAB | 3.5624% |
| Top 10 Holdings Weight: | 37.9% |
| Number of Holdings: | 31 |
| Shares Outstanding: | 10,900,002 |
| Total Net Assets: | 2,894,637,312 |
| NAV: | 265.54 |
| Net Expense Ratio: | 0.55% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
